Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2018

22.06.2018 | Original Article

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

verfasst von: Kazuto Ito, Shiro Saito, Atsunori Yorozu, Shinsuke Kojima, Takashi Kikuchi, Satoshi Higashide, Manabu Aoki, Hirofumi Koga, Takefumi Satoh, Toshio Ohashi, Katsumasa Nakamura, Norihisa Katayama, Nobumichi Tanaka, Masahiro Nakano, Naoyuki Shigematsu, Takushi Dokiya, Masanori Fukushima, For the J-POPS Investigators

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in terms of biochemical relapse-free survival (bRFS) by the Phoenix and the newly developed J-POPS definitions, exploration of predictive factors for bRFS, and preliminary verification of pitfalls of prostate-specific antigen (PSA) failure definitions.

Methods

Between July 2005 and June 2007, 2316 clinically localized patients underwent permanent seed implantation. The primary endpoint was bRFS. One of the secondary endpoints was overall survival (OS).

Results

The median age was 69 and performance status was 0 in 99.1% of participants. The median biologically effective dose (BED) was about 180 Gy2. During a median follow-up of 60.0 months, 8.4 and 5.9% had PSA failure by the Phoenix and the J-POPS definitions, respectively. The 5-year bRFSs based on the Phoenix and the J-POPS definitions were 89.1 and 91.6%, respectively. The 5-year OS was 97.3%. According to multivariate analyses, only age affected bRFS based on the Phoenix definition, whereas the risk group and BED independently affected bRFS based on the J-POPS definition. A spontaneous PSA decrease was seen in 91.1% of participants after PSA failure based on the Phoenix definition alone, but in only 22.2% after PSA failure based on the J-POPS definition alone.

Conclusion

The world’s largest registration study, J-POPS, consisted of patients with longevity, and a highly quality-controlled BED resulted in excellent bRFS and OS. The high likelihood of PSA bounce by the Phoenix definition should be taken into account, especially in younger patients.

Clinical trial information

NCT00534196.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
3.
Zurück zum Zitat Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29CrossRef Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29CrossRef
4.
Zurück zum Zitat Peinemann F, Grouven U, Bartel C et al (2011) Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60:881–893CrossRef Peinemann F, Grouven U, Bartel C et al (2011) Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60:881–893CrossRef
5.
Zurück zum Zitat Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69:338–342CrossRef Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 69:338–342CrossRef
6.
Zurück zum Zitat Waterman FM, Dicker AP (2003) Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55:342–353CrossRef Waterman FM, Dicker AP (2003) Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55:342–353CrossRef
7.
Zurück zum Zitat Saito S, Ito K, Yorozu A et al (2015) Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). Int J Clin Oncol 20:375–385CrossRef Saito S, Ito K, Yorozu A et al (2015) Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS). Int J Clin Oncol 20:375–385CrossRef
8.
Zurück zum Zitat Stock RG, Stone NN, Cesaretti JA et al (2006) Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64:527–533CrossRef Stock RG, Stone NN, Cesaretti JA et al (2006) Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64:527–533CrossRef
9.
Zurück zum Zitat Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974CrossRef Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974CrossRef
10.
Zurück zum Zitat Thames H, Kuban D, Levy L et al (2003) Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929–943CrossRef Thames H, Kuban D, Levy L et al (2003) Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929–943CrossRef
11.
Zurück zum Zitat Crook J, Gillan C, Yeung I et al (2007) PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 69:426–433CrossRef Crook J, Gillan C, Yeung I et al (2007) PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 69:426–433CrossRef
12.
Zurück zum Zitat Mazeron R, Bajard A, Montbarbon X et al (2012) Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence. Radiat Oncol 7:46CrossRef Mazeron R, Bajard A, Montbarbon X et al (2012) Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence. Radiat Oncol 7:46CrossRef
13.
Zurück zum Zitat Zwahlen DR, Smith R, Andrianopoulos N et al (2011) Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy—an Australian analysis. Int J Radiat Oncol Biol Phys 79:179–187CrossRef Zwahlen DR, Smith R, Andrianopoulos N et al (2011) Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy—an Australian analysis. Int J Radiat Oncol Biol Phys 79:179–187CrossRef
14.
Zurück zum Zitat Satoh T, Ishiyama H, Matsumoto K et al (2009) Prostate-specific antigen ‘bounce’ after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int 103:1064–1068CrossRef Satoh T, Ishiyama H, Matsumoto K et al (2009) Prostate-specific antigen ‘bounce’ after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis. BJU Int 103:1064–1068CrossRef
15.
Zurück zum Zitat McGrath SD, Antonucci JV, Fitch DL et al (2010) PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy 9:137–144CrossRef McGrath SD, Antonucci JV, Fitch DL et al (2010) PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy 9:137–144CrossRef
16.
Zurück zum Zitat Thompson A, Keyes M, Pickles T et al (2010) Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78:415–421CrossRef Thompson A, Keyes M, Pickles T et al (2010) Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78:415–421CrossRef
17.
Zurück zum Zitat D’Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821–827CrossRef D’Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821–827CrossRef
18.
Zurück zum Zitat D’Amico AV1, Chen MH, Renshaw AA et al (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295CrossRef D’Amico AV1, Chen MH, Renshaw AA et al (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299:289–295CrossRef
19.
Zurück zum Zitat Critz FA, Levinson AK, Williams WH et al (1997) The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 49:668–672CrossRef Critz FA, Levinson AK, Williams WH et al (1997) The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 49:668–672CrossRef
20.
Zurück zum Zitat Pickles T, Kim-Sing C, Morris WJ et al (2003) Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57:11–18CrossRef Pickles T, Kim-Sing C, Morris WJ et al (2003) Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57:11–18CrossRef
21.
Zurück zum Zitat Stone NN, Stock RG, Cesaretti JA et al (2010) Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76:355–360CrossRef Stone NN, Stock RG, Cesaretti JA et al (2010) Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 76:355–360CrossRef
22.
Zurück zum Zitat Ho AY, Burri RJ, Cesaretti JA et al (2009) Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 75:16–22CrossRef Ho AY, Burri RJ, Cesaretti JA et al (2009) Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 75:16–22CrossRef
23.
Zurück zum Zitat Stone NN, Potters L, Davis BJ et al (2009) Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73:341–346CrossRef Stone NN, Potters L, Davis BJ et al (2009) Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73:341–346CrossRef
24.
Zurück zum Zitat Ohashi T, Yorozu A, Saito S et al (2015) Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: nationwide J-POPS multi-institutional prospective cohort study. Int J Radiat Oncol Biol Phys 93:141–149CrossRef Ohashi T, Yorozu A, Saito S et al (2015) Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: nationwide J-POPS multi-institutional prospective cohort study. Int J Radiat Oncol Biol Phys 93:141–149CrossRef
26.
Zurück zum Zitat Miki K, Kiba T, Sasaki H et al (2010) Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 10:572CrossRef Miki K, Kiba T, Sasaki H et al (2010) Transperineal prostate brachytherapy, using I-125 seed with or without adjuvant androgen deprivation, in patients with intermediate-risk prostate cancer: study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 10:572CrossRef
27.
Zurück zum Zitat Konaka H, Egawa S, Saito S et al (2012) Tri-modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 12:110CrossRef Konaka H, Egawa S, Saito S et al (2012) Tri-modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial. BMC Cancer 12:110CrossRef
Metadaten
Titel
Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival
verfasst von
Kazuto Ito
Shiro Saito
Atsunori Yorozu
Shinsuke Kojima
Takashi Kikuchi
Satoshi Higashide
Manabu Aoki
Hirofumi Koga
Takefumi Satoh
Toshio Ohashi
Katsumasa Nakamura
Norihisa Katayama
Nobumichi Tanaka
Masahiro Nakano
Naoyuki Shigematsu
Takushi Dokiya
Masanori Fukushima
For the J-POPS Investigators
Publikationsdatum
22.06.2018
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1309-0

Weitere Artikel der Ausgabe 6/2018

International Journal of Clinical Oncology 6/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.